Zhuxuan Jiang's questions to I-Mab (IMAB) leadership • H1 2023
Question
Zhuxuan Jiang asked for more details about the company's plans for its early-stage pipeline development.
Answer
CEO Raj Kannan explained that the new corporate strategy prioritizes accelerating the current clinical-stage assets to maximize shareholder value over the next 2-5 years. While the early-stage R&D foundation in China remains important, the immediate focus has shifted to advancing the late-stage pipeline. Focus will return to earlier assets once the current programs are more mature.